Table 1.
Model parameters.
| Variable | Baseline value | Range | Reference | |
|---|---|---|---|---|
| Minimum | Maximum | |||
| NI: Log-normal PFS survival mode | λ = 1.93843, γ = 1.26135 | – | – | Peters et al. 10 |
| C: Log-logistic PFS survival mode | λ = 7.53780, γ = 2.29427 | – | – | Peters et al. 10 |
| NI: OS survival mode | ||||
| NI-A: WeibullPH OS survival mode | λ = 0.0241553, γ = 1.1284343 | – | – | Peters et al. 10 |
| NI-E: Log-logistic OS survival mode | λ = 19.01452, γ = 1.51241 | – | – | Peters et al. 10 |
| NI-N: Exponential OS survival mode | λ = 0.0412831 | – | – | Peters et al. 10 |
| C: OS survival mode | ||||
| C-A: Log-logistic OS survival mode | λ = 14.25065, γ = 1.76236 | – | – | Peters et al. 10 |
| C-E: Log-logistic OS survival mode | λ = 16.70245, γ = 1.70694 | – | – | Peters et al. 10 |
| C-N: Log-logistic OS survival mode | λ = 9.03382, γ = 2.15601 | – | – | Peters et al. 10 |
| NI: Incidence of AEs | ||||
| Asthenia | 0 | – | – | Peters et al. 10 |
| Anemia | 0.003 | 0.0024 | 0.0036 | Peters et al. 10 |
| Neutropenia | 0.007 | 0.0056 | 0.0084 | Peters et al. 10 |
| C: Incidence of AEs | ||||
| Asthenia | 0.042 | 0.0336 | 0.0504 | Peters et al. 10 |
| Anemia | 0.113 | 0.0904 | 0.1356 | Peters et al. 10 |
| Neutropenia | 0.151 | 0.1208 | 0.1812 | Peters et al. 10 |
| Utility | ||||
| PFS | 0.706 | 0.5648 | 0.8472 | Dansk et al. 22 |
| PD | 0.565 | 0.4520 | 0.6780 | Dansk et al. 22 |
| Death | 0 | – | – | Dansk et al. 22 |
| Asthenia | −0.410 | −0.3280 | −0.4920 | Nafees et al. 23 |
| Anemia | −0.073 | −0.0584 | −0.0876 | Wan et al. 24 |
| Neutropenia | −0.460 | −0.3680 | −0.5520 | Nafees et al. 23 |
| Drug cost per mg, 2022 US$ | ||||
| Nivolumab | 29.2450 | 14.6225 | 29.245 | Centers for Medicare and Medicaid Services 13 |
| Ipilimumab | 160.7030 | 80.3515 | 160.703 | Centers for Medicare and Medicaid Services 13 |
| Pemetrexed | 7.6037 | 6.08296 | 9.12444 | Centers for Medicare and Medicaid Services 13 |
| Cisplatin | 0.1864 | 0.14912 | 0.22368 | Centers for Medicare and Medicaid Services 13 |
| Carboplatin | 0.0522 | 0.04176 | 0.06264 | Centers for Medicare and Medicaid Services 13 |
| Vinorelbine | 0.8624 | 0.68992 | 1.03488 | Centers for Medicare and Medicaid Services 13 |
| Gemcitabine | 0.0192 | 0.01536 | 0.02304 | Centers for Medicare and Medicaid Services 13 |
| Drug administration and follow-up, cost per cycle, 2022 US$ | ||||
| Administration IV, first hour | 142.22 | 113.776 | 170.664 | Centers for Medicare and Medicaid Services 25 |
| Administration IV, additional hour | 30.68 | 24.544 | 36.816 | Centers for Medicare and Medicaid Services 25 |
| Outpatient follow-up visit | 52.33 | 41.864 | 62.796 | Centers for Medicare and Medicaid Services 25 |
| AEs cost per 1-month cycle, 2020 US$ | ||||
| Asthenia | 1065.44 | 852.352 | 1278.528 | Courtney et al. 26 |
| Anemia | 5243.47 | 4194.776 | 6292.164 | Courtney et al. 26 |
| Neutropenia | 16,857.15 | 13,485.720 | 20,228.580 | Courtney et al. 26 |
| Body area surface/m2 | 1.8 | 1.44 | 2.16 | Goulart and Ramsey 27 |
| Weight/kg | 70 | 56 | 84 | Goulart and Ramsey 27 |
| Creatinine clearance/mL/min | 70 | – | – | Goulart and Ramsey 27 |
| Discount rate | 0.03 | 0 | 0.06 | Bousmah et al. 16 |
A, all randomized patients; AEs, adverse events; C, pemetrexed plus cisplatin/carboplatin; E, patients with epithelioid histology; IV, intravenous injection; N, patients with non-epithelioid histology; NI, nivolumab plus ipilimumab; OS, overall survival; PD, progressed disease; PFS, progression-free survival.